Simulations Plus, Inc. (SLP)

NASDAQ: SLP · IEX Real-Time Price · USD
63.19
+0.65 (1.04%)
Aug 18, 2022 4:00 PM EDT - Market closed
1.04%
Market Cap 1.28B
Revenue (ttm) 52.01M
Net Income (ttm) 11.83M
Shares Out 20.24M
EPS (ttm) 0.57
PE Ratio 110.86
Forward PE 97.09
Dividend $0.24 (0.38%)
Ex-Dividend Date Jul 22, 2022
Volume 60,085
Open 62.97
Previous Close 62.54
Day's Range 61.99 - 63.65
52-Week Range 35.18 - 67.59
Beta 0.42
Analysts Buy
Price Target 62.48 (-1.1%)
Earnings Date Jul 6, 2022

About SLP

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematic... [Read more...]

Industry Health Care Technology
IPO Date Jun 18, 1997
Employees 135
Stock Exchange NASDAQ
Ticker Symbol SLP
Full Company Profile

Financial Performance

In 2021, SLP's revenue was $46.47 million, an increase of 11.73% compared to the previous year's $41.59 million. Earnings were $9.78 million, an increase of 4.82%.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for SLP stock is "Buy." The 12-month stock price forecast is 62.48, which is a decrease of -1.12% from the latest price.

Price Target
$62.48
(-1.12% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today a new collaboration to enhance ADMET Predictor, its preeminent property prediction platform for drug discovery.

Simulations Plus Presented New Scientific Developments at PAGE 2022

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus MonolixSuite modeling & simulation software was featured in several scientific posters at PAGE 2022 in Ljubljana, Slovenia.

Here's Why Simulations Plus (SLP) is a Great Momentum Stock to Buy

Does Simulations Plus (SLP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childho...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus continues its 25th anniversary celebration with a $25,000 donation to St. Jude Children's Research Hospital.

Simulations Plus Realizes Early Success with its Concierge Program

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus launches its Concierge Program to facilitate value-added strategic partnerships with customers to accelerate drug development.

Simulations Plus (SLP) Q3 Earnings & Revenues Top Estimates

Simulations Plus' (SLP) Q3 results benefit from strength in the Software and Services' business.

Simulations Plus (SLP) Q3 Earnings and Revenues Surpass Estimates

Simulations Plus (SLP) delivered earnings and revenue surprises of 17.65% and 5.94%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports 3QFY22 total revenue growth of 17%; YTD total revenue up 15%, to $42.2 million. Quarterly dividend was declared by the Board.

Kornit Digital, Simulations Plus And 3 Stocks To Watch Heading Into Wednesday

With the US stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Simulations Plus, Inc. (NASDAQ: SLP) to repo...

Other symbols: KRNT

What to Expect Ahead of Simulations Plus (SLP) Q3 Earnings?

Simulations Plus' (SLP) fiscal third-quarter performance is likely to reflect gains from strength in its diversified portfolio that includes offerings like GastroPlus and ADMET predictor.

Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus 2nd Annual Pharmacometrics Spring School introduced MonolixSuite and PKanalix platforms to more than 900 attendees from 50 countries.

Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that its Cognigen division worked with a major pharmaceutical company to accelerate the development of a COVID-19 therapy.

Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report 3rd quarter fiscal year 2022 financial results on Wed., July 6, 2022, with a webcast at 5pm ET.

DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced important results published in the journal Toxicological Sciences predicting the safety of new CGRP molecules for migraine.

Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the...

U.S. FDA Renews Annual DILIsym Software Licenses for 2022

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the FDA renewed annual licenses to DILIsym, the DILIsym division's QST software for predicting drug-induced liver injury.

Simulations Plus Successfully Delivers FDA-Funded Project

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus successfully establishes the suitability of model-integrated evidence for BE studies of LAI drug products in FDA-funded project.

Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus entered a funded collaboration to advance innovative IVIVE methods for dissolution and precipitation modeling in its DDDPlus software

Simulations Plus to Present at the Berenberg Discover AI Seminar

LANCASTER, Calif.--(BUSINESS WIRE)--Shawn O'Connor, chief executive officer of Simulations Plus, will be presenting at the Berenberg Discover AI Seminar in Boston, on April 26, 2022.

Simulations Plus (SLP) Q2 Earnings Top Estimates, Revenues Up

Simulations Plus (SLP) Q2 results benefit from strength in the Software business. However, a decline in Services revenues acted as a headwind.

Simulations Plus (SLP) Surpasses Q2 Earnings Estimates

Simulations Plus (SLP) delivered earnings and revenue surprises of 50% and 1.55%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports total revenue of $14.8 million, up 13%, for the 2nd quarter of FY22 with software revenue growth of 25%, to $9.8 million.

Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will partner with the University of Pittsburgh to develop and validate its novel BIOLOGXsym QST software with funding from the NIH.

Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus hosted its 2022 MIDD+ Scientific Conference on Feb. 16-17, 2022, with speakers from the US FDA, ANVISA, Health Canada, & MHRA-UK.

Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report 2nd quarter fiscal year 2022 financial results on Wed., April 6, 2022, with a webcast at 5pm ET.